Jordan Morton, MD
Hematology & Oncology · Oklahoma City, OKNPI 1659665867
Payments from drug & device makers
What this record shows
The money is spread across several categories — other (44.1%), food and beverage and education — rather than concentrated in one kind of arrangement. 38 manufacturers reported payments, led by Novartis at 53.0% of the total.
Across 239 payments — averaging $24.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$3K
- Pfizer$947
- Merck$212
- AbbVie$132
- Ipsen Biopharmaceuticals, Inc$112
- Incyte Corporation$108
- plus $1K from 32 others
Across 31 payments — averaging $670.81 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pharmacyclics LLC, An Abbvie Company$12K
- Helsinn Healthcare SA$9K
What the payments were for
- Food & beverage$2,58843%
- Education$74312%
- Other$2,63244%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 64 | $3,159 |
| Pfizer | 68 | $947 |
| Merck | 12 | $212 |
| AbbVie | 8 | $132 |
| Ipsen Biopharmaceuticals, Inc | 7 | $112 |
| Incyte Corporation | 6 | $108 |
| Astellas Pharma US Inc | 7 | $106 |
| E.r. Squibb & Sons, L.L.C. | 5 | $95 |
| Genentech USA, Inc. | 6 | $89 |
| Sumitomo Pharma America, Inc. | 3 | $77 |
| Johnson & Johnson | 5 | $69 |
| Daiichi Sankyo Inc. | 3 | $64 |
| Gilead | 4 | $62 |
| Amgen | 3 | $58 |
| Eisai Inc. | 3 | $49 |
| Sanofi | 3 | $45 |
| EMD Serono, Inc. | 2 | $42 |
| Bristol Myers Squibb | 2 | $42 |
| Sobi, Inc | 2 | $37 |
| Beigene USA, Inc. | 2 | $37 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $35 |
| Array Biopharma Inc | 3 | $35 |
| AstraZeneca(2 entities) | 2 | $35 |
| Seagen Inc. | 2 | $34 |
| Sirtex Medical Inc | 1 | $34 |
| G1 Therapeutics, Inc. | 2 | $31 |
| Kyowa Kirin, Inc. | 1 | $24 |
| Apellis Pharmaceuticals, Inc. | 1 | $23 |
| Sun Pharmaceutical Industries Inc. | 1 | $23 |
| Morphosys, US Inc. | 1 | $21 |
| ADC Therapeutics America, Inc. | 1 | $20 |
| Myovant Sciences Inc. | 1 | $17 |
| Global Blood Therapeutics, Inc. | 1 | $16 |
| Recordati_rare_diseases_inc. | 1 | $15 |
| Verastem, Inc. | 1 | $15 |
| Myriad Genetic Laboratories, Inc. | 1 | $15 |
| Rigel Pharmaceuticals, Inc. | 1 | $13 |
| Puma Biotechnology, Inc. | 1 | $13 |
How this compares
$5,963 in reported general payments places this provider in the 70th percentile of 118 hematology & oncology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ImbruvicaIbrutinib | 62 | $768,156 |
| RevlimidLenalidomide | 31 | $724,898 |
| LumakrasSotorasib | 26 | $555,720 |
| VenclextaVenetoclax | 39 | $494,830 |
| JakafiRuxolitinib Phosphate | 36 | $464,526 |
| KisqaliRibociclib Succinate | 34 | $463,831 |
| Lenalidomide | 20 | $372,368 |
| XtandiEnzalutamide | 20 | $265,806 |
| EliquisApixaban | 124 | $86,956 |
| Abiraterone Acetate | 32 | $54,135 |
| Imatinib Mesylate | 12 | $31,902 |
| MounjaroTirzepatide | 15 | $19,369 |
| OzempicSemaglutide | 13 | $18,035 |
| XareltoRivaroxaban | 16 | $11,605 |
| Letrozole | 124 | $3,468 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $35 | $768,15662 claims |
| Bristol Myers SquibbRevlimid | $42 | $724,89831 claims |
| AmgenLumakras | $58 | $555,72026 claims |
| AbbVieVenclexta | $132 | $494,83039 claims |
| Incyte CorporationJakafi | $108 | $464,52636 claims |
| NovartisKisqali | $3,159 | $463,83134 claims |
| Astellas Pharma US IncXtandi | $106 | $265,80620 claims |
| PfizerEliquis | $947 | $86,956124 claims |
| Johnson & JohnsonXarelto | $69 | $11,60516 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 118 hematology & oncology providers in Oklahoma.
Other hematology & oncology in Oklahoma City
- Romeo MandanasOklahoma City$160K
- Mohammad RazaqOklahoma City$56K
- Sami IbrahimiOklahoma City$41K
- Jennifer Holter-ChakrabartyOklahoma City$39K
- Hassan HatoumOklahoma City$23K
- Abdul Rafeh NaqashOklahoma City$23K
- Taha Al-JuhaishiOklahoma City$23K
- Adanma Anji Ayanambakkam AttanathiOklahoma City$16K
- Robert ReynoldsOklahoma City$15K
- Sadia ChohanOklahoma City$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.